Skip to main content
TipRanks
Go Ultimate75% OFF

InnoCare Pharma Ltd. (INCPF) Drug Pipeline

2 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Icp-332 TabletsHealthy SubjectsPhase ICompletedPhase I Study of ICP-332 in Healthy SubjectsJul 28, 2024―
Rituximab, Orelabrutinib, Bendamustine InjectionMantle Cell LymphomaPhase IIIRecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLApr 09, 2024
Icp-248, Obinutuzumab, RituximabMature B-Cell MalignanciesPhase IRecruitingEvaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesApr 02, 2024
Orelabrutinib High Dose, Orelabrutinib Low DoseMantle Cell LymphomaPhase IICompletedEvaluating Different Doses of Orelabrutinib in MCLJul 11, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does InnoCare Pharma Ltd. (INCPF) have in its pipeline
InnoCare Pharma Ltd. INCPF is currently developing the following drugs: Icp-332 Tablets, Rituximab, Orelabrutinib, Bendamustine Injection, Icp-248, Obinutuzumab, Rituximab, Orelabrutinib High Dose, Orelabrutinib Low Dose. These drug candidates are in various stages of clinical development as the company works toward FDA approval.